Podcasts about GSK

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen?

In this episode of Tank Talks, host Matt Cohen sits down with Roberto Bellini, Co-Founder of BSQUARED Capital and former CEO of Bellus Health, for a powerful conversation about family, legacy, and resilience in the world of biotech.Originally recorded just two weeks before the passing of his father, Dr. Francesco Bellini, one of the founding giants of Canadian biotech, this re-recorded episode serves as a moving tribute to the man known as “Mr. Biotech Canada.” Roberto opens up about what it was like growing up under the guidance of such a visionary figure and how that experience shaped his own path as an entrepreneur and leader.He reflects on the highs and lows of leading Bellus Health, from moments of near collapse to its remarkable $2 billion acquisition by GSK, sharing lessons on risk-taking, perseverance, and the importance of staying grounded through uncertainty. Roberto also offers his perspective on the future of Canadian biotech, highlighting the need for stronger late-stage funding and how BSquared Capital is helping to cultivate the next generation of innovators.This episode isn't just about business success; it's about honoring a legacy, learning through adversity, and discovering what it truly means to build something that endures.The Legacy of Dr. Francesco Bellini (00:02:52)* Francesco Bellini's incredible immigrant story: from arriving in Canada with nothing to a $6B biotech exit.* Business was the family's dinner table conversation, and attending AGMs as a child.* The founding of Biochem Pharma and the discovery of the groundbreaking HIV treatment.* “He was a visionary... he saw things before other people saw them.”Growing Up in Biotech (00:06:30)* Roberto's early memories of board meetings and dinner-table business lessons* How being “in the room” shaped his entrepreneurial mindset* Watching a $6B biotech deal become part of family historyThe Rise, Fall, and Rebirth of Bellus Health (00:08:27)* Roberto's journey from family office analyst to a 30-year-old, first-time CEO of a public company.* The devastating failure of the phase three trial for a rare kidney disease.* Inside a Biotech Failure: The intense, weekend-long “war room” process of unblinding clinical trial data and preparing for a public announcement.The Second Act: Finding the Cough Drug (00:13:47)* Discovering a promising molecule through the NeoMed Institute* Betting the company's future on a last-chance asset* Raising $20M when no one believed and turning it into a $2B successNegotiating the GSK Deal (00:24:45)* The strategic shift from “build-to-sell” to “build-to-scale”, positioning the company for a premium acquisition.* The M&A Playbook: Why you should never lead with a desire to sell; the importance of building for independence.* The high-stakes negotiation with GSK: going from an $11 offer to $14.75, almost losing the deal, and the “mellow tone” that saved it.* The entrepreneur's dilemma: “Every single entrepreneur I've met that sold their company, there's always a moment of not wanting to do it.”Building Canada's Biotech Future (00:30:11)* Why Canada has the innovation but lacks the enduring biotech giants.* The critical gap: The need for more late-stage capital and the role of Canadian pension funds.* The “Gilead of the North” vision: Creating a virtuous cycle of capital, entrepreneurs, and translational science.* Upcoming trends: The convergence of AI and drug discovery to de-risk development and lower costs.Beyond the Lab: Leadership, Risk, and Legacy (00:46:20)* Learning to embrace risk and find joy in reinvention* The best advice from Dr. B: “Spend your money, it'll make you want to earn more.”* Why true success isn't just building a company, but building peopleAbout Roberto BelliniFounder & Managing Partner, BSQUARED CapitalRoberto Bellini is a second-generation biotech entrepreneur and investor. As the former CEO of Bellus Health, he led the company's dramatic turnaround and eventual $2 billion acquisition by GSK. Drawing on his deep operational experience in drug development, he now co-manages BSQUARED Capital, a family office focused on investing in and supporting promising biotech ventures. He is a passionate advocate for building a stronger, more resilient biotech ecosystem in Canada.Connect with Roberto Bellini on LinkedIn: https://www.linkedin.com/in/robertobellini/Visit BSQUARED Capital Website: https://bsq-c.com/Connect with Matt Cohen on LinkedIn: https://ca.linkedin.com/in/matt-cohen1Visit the Ripple Ventures website: https://www.rippleventures.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit tanktalks.substack.com

Synopsis: Jim Tananbaum, Founder & CEO of Foresite Capital, joins Rahul Chaturvedi to dissect the patterns driving biotech innovation, the role of macroeconomic cycles in venture performance, and how disciplined science fuels enduring investment success. Drawing from three decades across entrepreneurship and venture leadership, Jim reflects on his path from co-founding drug discovery startups with Harvard collaborators to building one of the most respected investment firms in life sciences. He unpacks how interest rate environments shape fund vintages, why AI is emerging as the next transformative platform, and how investors can identify enduring opportunities amid volatility. Their discussion spans valuation compression, AI-driven discovery, CNS and Alzheimer's innovation, and the geopolitical forces influencing biotech globally. Jim's perspective offers a masterclass in balancing scientific rigor with strategic foresight — and in positioning capital where breakthrough innovation meets sustainable impact. “Lean into areas where there's likely to be immense change,” Jim advises — a principle as relevant to biotech investing as it is to shaping the future of healthcare itself. Biography: Jim is the founder and CEO of Foresite Capital, a healthcare investment firm founded in 2011 that has approximately $3.5B in assets under management. Jim assembles the people, ideas, and money needed to launch products that save lives and improve healthcare. During the last three decades, Jim has been a thought partner for some of the fastest-growing companies of their generation, including 10x Genomics (Nasdaq: TXG), Amerigroup (Nasdaq: ANTM), and Jazz Pharmaceuticals (Nasdaq: JAZZ). Jim's entrepreneurial experience began at Harvard Business School when he co-founded GelTex Pharmaceuticals (Nasdaq:GENZ). With less than $80M in funding, GelTex brought two drugs to market, and the company was acquired in 1999 for $1.4B. Jim was also the founding chief executive of Theravance, Inc. Under his tenure, he raised over $350M. Theravance has since split into two parts, one of which is now part of GSK's respiratory franchise through a joint venture, Innoviva (Nasdaq: INVA), and the other was spun out into Theravance Biopharma, Inc. (Nasdaq: TBPH). Together, they achieved a market capitalization that exceeded $4B. Jim's investment experience includes co-founding Prospect Ventures and, earlier in his career, being a partner of Sierra Ventures, where he established its healthcare services investment practice. Jim graduated from Yale with a BS and BSEE in Applied Math and Electrical Engineering/Computer Science. He then earned an MD from Harvard, graduating from the Harvard/MIT HST Program. He also earned an MBA from Harvard while playing rugby.

The Bank of England's (“BoE”) Monetary Policy Committee meets this Thursday to determine the UK's next interest rate decision, with markets broadly expecting rates to remain unchanged. However, a growing camp of analysts believes recent macroeconomic developments could tilt the balance towards a rate cut. Governor Andrew Bailey's vote will likely prove decisive, though the contrasting stances of Deputy Governors Sarah Breeden (dovish) and Clare Lombardelli (hawkish) underscore the committee's divisions. The meeting takes place against a backdrop of persistently weaker UK business sentiment, with the Institute of Directors' (“IoD”) confidence index registering lower, close to September's record low. On the inflation front, employers expect pay settlements to ease to 3%, and shop prices have fallen for the first time since March; both developments strengthen the case for a more dovish BoE stance...Stocks featured:Airtel Africa, GSK and WPPTo find out more about the investment management services offered by Walker Crips, please visit our website:https://www.walkercrips.co.uk/This podcast is intended to be Walker Crips Investment Management's own commentary on markets. It is not investment research and should not be construed as an offer or solicitation to buy, sell or trade in any of the investments, sectors or asset classes mentioned. The value of any investment and the income arising from it is not guaranteed and can fall as well as rise, so that you may not get back the amount you originally invested. Past performance is not a reliable indicator of future results. Movements in exchange rates can have an adverse effect on the value, price or income of any non-sterling denominated investment. Nothing in this podcast constitutes advice to undertake a transaction, and if you require professional advice you should contact your financial adviser or your usual contact at Walker Crips. Walker Crips Investment Management Limited is authorised and regulated by the Financial Conduct Authority (FRN: 226344) and is a member of the London Stock Exchange. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Season 5, Episode 44! Our guest today is Thien Ho, the Sacramento District attorney and long time prosecutor. He's also the author of the upcoming book, The People vs. The Golden State Killer which will be published by Third State Books and releases on November 11th. This true crime memoir follows Thien's experience as the lead prosecutor on the case against Joseph DeAngelo, one of the most notorious serial killers of the 20th century. It covers never-before published details about the investigation, capture, and trial that put DeAngelo behind bars. At the same time, the book is a memoir that follows Thien's personal story escaping war-torn Vietnam as a young boy and working his way up the law enforcement system to becoming the lead prosecutor in the case. Ho has gone on to become the Sacramento District Attorney, one of only 10 API District Attorneys in the country (there are 2400 total DAs).  We loved how the book also highlights the experiences of three key survivors of DeAngelo's crimes, something that other books on the Golden State Killer haven't done to any significant extent… and this gives power to the survivors. In fact, a portion of the book's proceeds will be donated both by the author and Third State Books to Phyllis's Garden, a nonprofit advocating for victims' rights begun in honor of a GSK survivor.  To get a copy of the book, we encourage you to purchase through the links on thienho.org because you'll be supporting small businesses.  If you like what we do, please share, follow, and like us in your podcast directory of choice or on Instagram @AAHistory101. For previous episodes and resources, please visit our site at https://asianamericanhistory101.libsyn.com or our links at http://castpie.com/AAHistory101. If you have any questions, comments or suggestions, email us at info@aahistory101.com.

Another vibrant morning at The Day After, the home of popular culture as defined by you - the culture. The team kicked off with laughs, community shoutouts, and reflections on viral clips, online debates, and the blurring line between real-world and digital accountability. They dissected podcast drama surrounding Tricky and Bouncer, exploring how online ego, “street rules,” and content creation collide.In the news:Labour leader Keir Starmer dodges tax-rise questions ahead of the budget.Hurricane Melissa leaves devastation across Jamaica and Cuba.GSK warns the UK risks losing its life-sciences edge without drug-pricing reform.Character.AI bans users under 18 amid child-safety lawsuits.Updates on the Gets case following a fatal hit-and-run.Then came a powerful and heartfelt interview with Bunmi Mojekwu - actress, writer, and filmmaker behind It's a BAM Productions. She opened up about:Growing from EastEnders to independent filmmaking.Navigating colorism, self-worth, and representation in media.Building a company that changes narratives through art.Her creative process - transforming single conversations into scripts inspired by music.BUNMI'S SHORT FILM 'THE PREQUEL' IS ON YOUTUBE: https://www.youtube.com/watch?v=B1kRFxEO828FOLLOW HERE ON IG:https://www.instagram.com/bunmimojekwu/?hl=enFOLLOW BAM PRODUCTIONS:https://www.instagram.com/bamproductionsltd/?hl=en

APAC stocks were predominantly in the green following the tech strength on Wall St, most indices extended to record highs.US President Trump said he had a great trip so far and expects to lower fentanyl-linked tariffs on China. China said to have made soybean purchase.European equity futures indicate a marginally lower cash market open with Euro Stoxx 50 future down 0.1% after the cash index closed with losses of 0.1% on Tuesday.USD is broadly firmer vs. peers with GBP still under pressure. AUD leads as hot Aus CPI dashes hopes of an RBA rate cut next month.Israeli planes launched strikes on Gaza City. US VP Vance said he thinks peace in the Middle East will hold despite skirmishes.Looking ahead, highlights US Pending Homes (Sep), FOMC & BoC Policy Announcements, US President Trump to meet South Korea's Leader, Fed Chair Powell & BoC's Macklem, Supply from UK, Germany & US.Earnings from Meta, Microsoft, Alphabet, Google, Starbucks, eBay, Verizon, Boeing, CVS, Caterpillar, Phillips 66, UBS, BASF, Mercedes-Benz, Deutsche Bank, Equinor, Santander, GSK & Airbus.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Dr. Andrew Lee, Vice President, Clinical Research at Uniquity Bio, about Thymic Stromal Lymphopoietin (TSLP) and eosinophilic esophagitis (EOE). Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:49] Co-host Ryan Piansky introduces the episode, brought to you thanks to the support of Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:13] Holly introduces today's topic, Thymic Stromal Lymphopoietin (TSLP) and eosinophilic esophagitis (EOE), and today's guest, Dr. Andrew Lee, Vice President, Clinical Research at Uniquity Bio.   [1:36] Dr. Lee has nearly 20 years of experience in the clinical development of new vaccines, biologics, and drugs. Holly welcomes Dr. Lee.   [1:52] Dr. Lee trained in internal medicine and infectious diseases.   [1:58] Dr. Lee has been fascinated by the immune system and how it can protect people against infections, what happens when immunity is damaged, as in HIV and AIDS, and how to apply that knowledge to boost immunity with vaccines to prevent infections.   [2:16] Dr. Lee led the clinical development for a pediatric combination vaccine for infants and toddlers. It is approved in the U.S. and the EU.   [2:29] Dr. Lee led the Phase 3 Program for a monoclonal antibody to prevent RSV, a serious infection in infants. That antibody was approved in June 2025 for use in the U.S.   [2:44] In his current company, Dr. Lee leads research into approaches to counteract an overactive immune system. They're looking at anti-inflammatory approaches to diseases like asthma, EoE, and COPD.   [2:58] Dr. Lee directs the ongoing Phase 2 studies that they are running in those areas.   [3:28] Dr. Lee sees drug development as a chance to apply cutting-edge research to benefit people. He trained at Bellevue Hospital in New York City in the 1990s.   [3:40] When Dr. Lee started as an intern, there were dedicated ICU wards for AIDS patients because many of the sickest patients were dying of AIDS and its complications.    [3:52] Before the end of Dr. Lee's residency, they shut down those wards because the patients were on anti-retroviral medications and were doing so well that they were treated as outpatients. They didn't need dedicated ICUs for AIDS patients anymore.   [4:09] For Dr. Lee, that was a powerful example of how pharmaceutical research and drug regimen can impact patients' lives for the better by following the science. That's what drove Dr. Lee to go in the direction of research.   [4:48] Dr. Lee explains Thymic Stromal Lymphopoietin (TSLP). TSLP serves as an alarm signal for Type 2 or TH2 inflammation, a branch of the immune responses responsible for allergic responses and also immunity against parasites.   [5:17] When the cells that line the GI tract and the cells that line the airways in our lungs receive an insult or an injury, they get a danger signal, then they make TSLP.   [5:28] This signal activates other immune cells, like eosinophils and dendritic cells, which make other inflammatory signals or cytokines like IL-4, IL-13, and IL-5.   [5:47] That cascade leads to inflammation, which is designed to protect the body in response to the danger signal, but in some diseases, when there's continued exposure to allergens or irritants, that inflammation goes from being protective to being harmful.   [6:15] That continued inflammation, over the years, can lead to things like the thickened esophagus with EoE, or lungs that are less pliant and less able to expand, in respiratory diseases.   [6:48] Dr. Lee says he thinks of TSLP as being a master switch for this branch of immune responses. If you turn on TSLP, that turns on a lot of steps that lead to generating an allergic type of response.   [7:06] It's also the same type of immune response that can fight off parasite infections. It's the first step in a cascade of other steps generating that type of immune response.   [7:30] Dr. Lee says people have natural genetic variation in the genes that incur TSLP.   [7:38] Observational studies have found that some people with genetic variations that lead to higher levels of TSLP in their bodies had an increased risk for allergic inflammatory diseases like EoE, atopic dermatitis, and asthma.   [8:13] Studies like the one just mentioned point to TSLP being important for increased risk of developing atopic types of diseases like EoE and others. There's been some work done in the laboratory that shows that TSLP is important for activating eosinophils.    [8:38] There's accumulating evidence that TSLP activation leads to eosinophil activation, other immune cells, or white blood cells getting activated.   [9:07] Like a cascade, those cells turn on T-cells and B-cells, which are like vector cells. They lead to direct responses to fight off infections, in case that's the signal that leads to the turning on TSLP.   [9:48] Ryan refers to a paper published in the American Journal of Gastroenterology exploring the role of TSLP in an experimental mouse model of eosinophilic esophagitis. Ryan asks what the researchers were aiming to find.   [10:00] Dr. Lee says the researchers were looking at the genetic studies we talked about, the observational studies that are beginning to link more TSLP with more risk for EoE and those types of diseases.   [10:12] The other type of evidence that's accumulating is from in vitro (in glass) experiments or test tube experiments, where you take a couple of cells that you think are relevant to what's going on.   [10:28] For example, you could get some esophageal cells and a couple of immune cells, and put TSLP into the mix, and you see that TSLP leads to activation of those immune cells and that leads to some effects on the esophageal cells.   [10:42] Those are nice studies, but they're very simplified compared to what you can do in the body. These researchers were interested in extending those initial observations from other studies, but working in the more realistic situation of a mouse model.   [11:00] You have the whole body of the mouse being involved. You can explore what TSLP is doing and model a disease that closely mimics what's happening with EoE in humans.   [12:23] They recreated the situation of what seems to be happening in EoE in people. We haven't identified it specifically, but there's some sort of food allergen in patients with EoE that the immune system is set off by.   [12:55] What researchers are observing in this paper is that in these mice that were treated with oxazolone, there is inflammation in the esophagus, an increase in TSLP levels, and eosinophils going into the esophageal tissues.   [13:15] Dr. Lee says, that's one of the main ways we diagnose EoE; we take a biopsy of the esophagus and count how many eosinophils there are. Researchers saw similar findings. The eosinophil count in the esophageal tissues went way up in these mice.    [13:34] Researchers also saw other findings in these mice that are very similar to EoE in humans, such as the esophageal cells lining the esophagus proliferating. They even saw that new blood vessels were being created in that tissue that's getting inflamed.   [14:00] Dr. Lee thinks it's a very nice paper because it shows that correlation: Increase TSLP and you see these eosinophils going to the esophagus, and these changes that are very reminiscent of what we see in people with EoE.   [14:51] In this paper, the mice made the TSLP, and researchers were able to measure the TSLP in the esophageal tissue. The researchers didn't introduce TSLP into the mice. The mice made the TSLP in response to being repeatedly exposed to oxazolone.   [15:20] That's key to the importance of the laboratory work. The fact that the TSLP is made by the mice is important. It makes it a very realistic model for what we're seeing in people.   [15:41] In science, we like to see correlation. The researchers showed a nice correlation.   [15:46] When TSLP went up in these mice, and the mice were making more TSLP on their own, at the same time, they saw all these changes in the esophagus that look a lot like what EoE looks like in people.    [16:01] They saw the eosinophils coming into the esophagus. They saw the inflammation go up in the esophagus. What Dr. Lee liked about this paper is that they continued the story.   [16:15] The researchers took something that decreases TSLP levels, an antibody that binds to and blocks TSLP, and when they did that, they saw the TSLP levels come down to half the peak level.   [16:35] Then they saw improvement in the inflammation in the esophagus. They saw that the amount of eosinophils decreased, and the multiplication of the esophageal cells went down. The number of new blood vessels went down after the TSLP was reduced.   [16:53] Dr. Lee says, you see correlation. The second part is evidence for causation. When you take TSLP away, things get better. That gives us a lot of confidence that this is a real finding. It's not just observational. There is causation evidence here.   [18:26] Ryan asks if cutting TSLP also help reduce other immune response cells. Dr. Lee says TSLP is the master regulator for this Type 2 inflammation. It definitely touches and influences other cells besides eosinophils.   [18:44] TSLP affects dendritic cells, which are an important type of immune cell, like a coordinating cell that instructs other cells within the immune system what to do. In this paper, they looked at a lot of other effects of TSLP on the tissues of the body.   [19:10] Dr. Lee says, There's a lot of research on TSLP, and one of the reasons we're excited about the promise of TSLP is that it's so far upstream; so much of the beginning, that it's affecting other cells.   [19:29] Its effects could be quite broad. If we're able to successfully block TSLP, we could block a lot of different effects.   [19:40] One treatment for EoE is dupilumab, which blocks IL-4 and IL-13 specifically, and that works well, but TSLP has the potential to have an even greater effect than blocking IL-4 and IL-13, since it is one step before turning on IL-4 and IL-13.    [20:14] That's one of the reasons researchers are excited about the promise of blocking TSLP. There are studies ongoing of TSLP blockers in people with EoE.   [20:34] Ryan asks if there are negative repercussions from blocking TSLP. Dr. Lee says in this study and in people, we are not completely blocking TSLP by any means. There will still be residual TSLP activated, even with very potent drugs.   [21:01] In the study, they block TSLP about 50%‒60%. TSLP is involved in immunity against parasites. In studies with people, they make sure not to include anybody who has an active parasitic infection. A person under treatment should not be in a study.   [21:27] Dr. Lee says we haven't seen any problems with parasitic infections becoming more severe, but that is a theoretical possibility, so for that reason, in studies with TSLP blockers, we generally exclude patients with known parasitic infections.   [22:17] What excited Dr. Lee in this paper was that they showed that when you block TSLP in the mice, then you get real effects in their tissues. Eosinophils went away. The thickening of the basal layers in the esophagus got much better.   [22:38] That kind of real effect reflected in the tissue is super exciting to see. That gives us more confidence that this could work in people, since we're seeing it in a realistic whole-body model in the mice.   [23:12] Dr. Lee says there are ongoing clinical studies on TSLP blockers for EoE. His company is studying an antibody that blocks TSLP in eczema, COPD, and EoE. One of the exciting things about immunology is that it affects many different parts of the body.   [23:42] EoE is associated with other immune-type disorders. There's a high percentage of patients with EoE who have other diseases. EoE coexists with asthma, atopic dermatitis, and chronic rhinitis.   [24:09] It's exciting that if you figure out something that's promising for one disease that TSLP affects, it could have very broad-ranging implications for a variety of diseases.   [24:22] Ryan shares his experience of his doctor talking to him about a TSLP blocker, tezepelumab, as a potential option when it's out of clinical trials. It would target something a little higher up the chain and help with some of his remaining symptoms.   [24:59] Ryan is excited to hear that this research is so encouraging and how it could potentially help treat EoE, asthma, and other conditions, all at once.   [25:16] Dr. Lee says that being in these later-stage studies is super exciting. If these late-stage trials are successful, the next step is to apply for regulatory approval with the various agencies around the world.   [26:40] Dr. Lee shares one takeaway for listeners to remember. Think of TSLP as an alarm that turns on inflammation. He compares TSLP to turning on an alarm during a robbery. There are multiple steps designed to protect the bank and the money.   [27:20] To extend that analogy, with TSLP, once you turn it on, all these other steps are going to happen. Inflammation is designed to protect the body. It's a protective response. If there's an infection, it can clear the infection.   [27:38] If the infection persists, as in HIV, the immune response, which is protective and beneficial, eventually becomes damaging. It becomes dysfunctional. In EoE, if you continually eat the allergic food, the inflammation becomes damaging to the esophagus.   [28:27] Long-term inflammation leads to replacing the normal esophageal tissue with fibrotic tissue, and that's why the esophagus eventually gets hardened and less able to let the food go through.   [28:40] In respiratory diseases, the soft tissue of the lung gets replaced with thicker tissue, and the lung is not able to expand.   [28:54] Dr. Lee says he people to think about TSLP as this master alarm switch. We hope that if you could turn off that TSLP, you could then avoid a lot of the complications that we see with chronic inflammation in these conditions.   [29:14] We're hopeful that you could even take away the symptoms that you see in these diseases, make patients feel better, and with extended treatment, you could begin to reverse some of the damage resulting from inflammation.   [29:32] Ryan likes that analogy and how Dr. Lee has concisely explained these complicated concepts.   [29:51] Dr. Lee thanks Holly and Ryan and adds one more plea to listeners. Please consider getting involved with research. Clinical trials cannot be done without patients. We need patients to advance new treatments.   [30:27] Researchers like Dr. Lee spend a lot of time thinking about how to make the studies not only informative but also fair to patients who decide to become involved. It's a lot of work and a fair amount of time commitment.   [30:44] If you don't want to be in a study, you can help by being on a patient feedback panel and reviewing protocols and informed consents. Follow your interests. Think about getting involved with research, however you can.   [31:06] Ryan and Holly are very grateful for the community, with so many wonderful clinicians and researchers, and so many patients who are willing to volunteer their time and their data to help researchers find better solutions going forward.   [31:26] Ryan thanks Dr. Lee for coming on and putting out that call to action. It's a great reminder for listeners and the patients in the community to look for those opportunities. Chat with your physician. Go to APFED's website. There's a link to active clinical trials.   [31:47] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes below.   [31:53] For those looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [32:01] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [32:11] Ryan thanks Dr. Andrew Lee for joining us today. We learned a lot. Holly also thanks APFED's Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Andrew Lee, M.D., VP Clinical Research, Uniquity Bio   "A Mouse Model for Eosinophilic Esophagitis (EoE)" Current Protocols, Wiley Online Library   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "I see drug development as a chance to apply cutting-edge research to benefit people." — Andrew Lee, M.D.   "When the cells that line the GI tract and the cells that line the airways in our lungs receive an insult or an injury, they get a danger signal, then they make TSLP." — Andrew Lee, M.D.   "Observational studies have found that some people with genetic variations that lead to higher levels of TSLP in their bodies had an increased risk for allergic inflammatory diseases like EoE, atopic dermatitis, and asthma." — Andrew Lee, M.D.   "There's a lot of research on TSLP, and one of the reasons we're excited about the promise of TSLP is that it's so far upstream; so much of the beginning, that it's affecting other cells." — Andrew Lee, M.D.   "Please consider getting involved with research. We can't do these clinical trials without patients. We need patients to advance new treatments for patients." — Andrew Lee, M.D.

Un accord à 300 millions d'euros pour une société strasbourgeoise. Le laboratoire pharmaceutique anglais GSK a révélé hier avoir acheté les droits exclusifs d'un anticorps créé par l'entreprise de biotechnologie Syndivia. Une technologie qui permettrait de réaliser des traitements de nouvelle génération contre le cancer de la prostate, le cancer le plus fréquent chez les hommes. Des études précliniques auraient montré une réduction significative de la taille des tumeurs sans provoquer d'augmentation proportionnelle des effets secondaires graves, même à des doses élevées.Du changement au 152e régiment d'infanterie à Colmar ! La 5e compagnie des Diables rouges a officiellement été recréée vendredi dernier, trois ans après sa dissolution. Cette dernière, composée de 130 réservistes, marque le renforcement du dispositif de défense. Les militaires de la compagnie se rendront prochainement dans le Jura, dans le cadre d'un premier exercice. L'Alsace représentée à la finale du MAF Chocolaterie Confiserie. Eva Perrinel, formée au CMA Formation Bernard Stalter à Eschau, avait été sélectionnée à l'échelle régionale en septembre dernier grâce à ses réalisations en hommage à Olympe de Gouges, en marge du thème 2025 “Les femmes de l'Histoire”. Maintenant, l'heure est à la finale nationale qui se déroule aujourd'hui à Paris. Les résultats et la remise des prix se tiendront demain à 11h, sur la scène du Cacao Show au Salon du Chocolat et de la Pâtisserie.L'association Entraide Le Relais tire la sonnette d'alarme. Cette dernière, qui gère deux maisons d'hébergement de personnes en précarité à Brumath s'inquiète, à l'heure de la préparation du budget 2026. L'association fait face à une difficulté supplémentaire : la fin du financement de la Collectivité européenne d'Alsace. Une mauvaise nouvelle annoncée en mars dernier et qui représenterait une perte cumulée de 86 000 euros. Depuis, plusieurs lettres ont été envoyées par  Entraide Le Relais, mais sont restées sans réponse. Une réunion, initialement prévue, a aussi été annulée. De son côté, la Collectivité européenne d'Alsace a indiqué auprès de nos confrères des Dernières Nouvelles d'Alsace être sur le dossier et attendre des discussions avec les responsables de l'Etat, pour qui elle finance historiquement l'hébergement des personnes précaires. Des bénévoles se mobilisent à Colmar. Jusqu'à vendredi, une opération de sensibilisation est organisée par la municipalité juste avant la Toussaint et la mise en place de nouvelles consignes pour le tri des déchets. Dès ce samedi 01 novembre, différents panneaux seront installés et indiqueront les points dédiés pour chaque type de déchet que l'on pourrait retrouver. Avant ces changements, des personnes volontaires accueillent donc cette semaine les usagers et répondront à d'éventuelles questions, de 10 h à 12 h et de 14 h à 16 h.Deux voitures impliquées dans un accident de la route hier après-midi. Après 16h, deux véhicules sont entrés en collision sur la RD 210, entre Ebersheim et Dambach-la-Ville. Au total, huit personnes étaient à bord de ces deux voitures lors de l'accident. Parmi ces occupants, âgés de 17 à 23 ans, deux personnes ont été transportées à l'hôpital de Sélestat par les pompiers.La frite était à l'honneur le week-end dernier à Mittelbergheim ! La commune a organisé dimanche une fête pour honorer la Mittelbergheimoise Sophie Coindre, sacrée championne du monde de la frite à Arras dans le Pas-de-Calais il y a un mois, dans la catégorie “frites familiales”. 200 kilos de frites maisons ont été concoctés à l'occasion, à partir de pommes de terre venant d'une exploitation basée à Meistratzheim.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

Impfstrategien bei rheumatologischen Patient*innen Menschen mit rheumatologischen Erkrankungen haben ein erhöhtes Risiko für eine Gürtelrose. Warum das so ist und wie dem Risiko begegnet werden kann, das erfahren Sie in der aktuellen Folge der Podcast-Serie „O-Ton Allgemeinmedizin Extra“ mit Prof. Dr. Klaus Krüger, niedergelassener Rheumatologe in München. Aktive Erkrankung und einige Therapieoptionen erhöhen das Risiko Menschen mit aktiven entzündlichen rheumatischen Erkrankungen wie rheumatoider Arthritis, Psoriasis-Arthritis oder systemischem Lupus erythematodes (SLE) haben ein erhöhtes Risiko für Herpes zoster. Aber auch Therapeutika wie z.B. Glukokortikoide oder JAK-Inhibitoren können das Herpes-zoster-Risiko der Betroffenen erhöhen. Und: Kommt es beispielsweise unter Biologika zu einer Gürtelrose, verläuft diese oft schwer und hat eine erhöhte Komplikationsrate. Es gibt also genügend Gründe für eine effektive Prävention. Das sagt die STIKO Die Ständige Impfkommission (STIKO) empfiehlt eine Impfung gegen Herpes zoster generell für alle Menschen ab 60 Jahren. Personen mit einem chronischen Leiden wie z. B. einer rheumatolgischen Erkrankung sollen bereits ab 50 Jahren geimpft werden. In diesen Fällen wird die Impfung regelhaft durch die Kostenträger übernommen. Eine Sondersituation gibt es bei Patient*innen mit SLE, da diese bereits im Alter von 20 bis 30 Jahren erkranken. Krüger rät auch diese Patient*innen gegen Gürtelrose zu impfen und dafür die Kostenübernahme bei der jeweiligen Krankenkasse zu beantragen. Der Totimpfstoff ist anhaltend wirksam und hat ein gutes Sicherheitsprofil. Diese Podcast-Episode ist mit freundlicher Unterstützung von GSK entstanden. Zur Folgen-Übersicht: https://bit.ly/4hoYfbK

On this week's episode, Chris Garabedian, Brian Skorney, and Sam Fazeli open with optimism about the biotech market, predicting an upcoming acceleration in IPO activity. In deals and financing news, the co-hosts discussed Summit Therapeutics' $500 million raise, with more than half coming from insiders, and continued momentum in M&A, including Alkermes' $2.1 billion acquisition of Avadel for its narcolepsy drug. The group also highlighted Takeda's $1.2 billion oncology deal with Innovent. European biotech funding showed positive signs, evidenced by Tubulis' $360 million Series C. Next, the co-hosts recapped ESMO, spotlighting Summit and Akeso's NSCLC data, Incyte's KRAS G12D inhibitor, and Arcus and AstraZeneca's TIGIT data. The episode concluded with additional data readouts, including mixed results from Alector and GSK's dementia drug, and Moderna's CMV mRNA vaccine results. *This episode aired on October 24, 2025.

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones, and groundbreaking scientific advancements that are shaping the future of drug development and patient care.Let's begin with a major corporate shakeup at Novo Nordisk. The company has announced a significant leadership transition as former CEO Lars Rebien Sorensen is set to become the new chairman of the board. This change follows the resignation of seven board members and indicates a strategic realignment within the company. The Novo Foundation's involvement suggests a deeper strategic shift, potentially aligning with new organizational objectives and innovations. Such moves are pivotal as they could influence Novo Nordisk's market position and future product development.Turning to scientific breakthroughs, Merck's collaboration with Kelun-Biotech has yielded promising results with their Trop2 antibody-drug conjugate, sacituzumab-tmt. This ADC has shown success in two Phase 3 trials targeting lung and breast cancers, underscoring the therapeutic potential of ADCs in oncology. By selectively targeting cancer cells while minimizing damage to healthy tissues, ADCs could significantly improve patient outcomes and represent a powerful modality in cancer treatment.In regulatory affairs, Kenvue is challenging the FDA over proposed safety warnings for Tylenol linked to autism during pregnancy. This dispute highlights the ongoing debates surrounding drug safety and regulatory oversight. The outcome could have significant implications for labeling practices and consumer trust in over-the-counter medications. Meanwhile, Summit Therapeutics plans to file for FDA approval of ivonescimab, highlighting ongoing innovation in drug development pipelines. Similarly, Novo Nordisk's semaglutide pill Rybelsus has received FDA expansion approval to reduce major adverse cardiovascular events. This sets a new benchmark for oral metabolism drugs by demonstrating their potential beyond glycemic control to positively impact cardiovascular health.As we explore industry trends, there's growing interest in direct-to-consumer drug sales. While this approach offers patients access to medications at reduced costs, it raises concerns about privacy and the quality of care without traditional healthcare provider interactions. Additionally, a notable decline in pharmaceutical TV ad spending by 19% in Q3 suggests a shift towards digital engagement strategies. Amidst these narratives, the Biotechnology Innovation Organization (BIO) has launched an awareness campaign to combat misinformation about vaccines. This effort underscores the importance of immunizations in public health and aims to reinforce trust amid rising disinformation.In another scientific advancement, GSK has released positive Phase 3 data for Spero Therapeutics' oral antibiotic candidate. The oral formulation's efficacy comparable to intravenous options could lead to broader use and improved patient adherence—critical advancements as antibiotic resistance remains a global health challenge.Investment activities reflect strategic shifts within the industry as well. Curewell Capital's investment in Wilmington PharmaTech aims to enhance U.S. active pharmaceutical ingredient production capacity—a crucial step given recent global supply chain disruptions. Similarly, India's ACG is making a $200 million investment in its first U.S. empty-capsule production facility, highlighting the strategic importance of manufacturing capabilities on American soil.Galapagos' decision to wind down its cell therapy unit marks a significant strategic pivot from its previous focus on this modality. This shift reflects broader industry trends where companies reassess priorSupport the show

“We have strong scientific foundations and manufacturing excellence. Now we're creating the ecosystem to help biotechs scale and compete globally,” says Federico Vigano, Board Member of Assobiotec.Federico Vigano, Country Manager for Vertex in Italy and Greece, brings extensive pharmaceutical leadership experience from roles at AstraZeneca, Boehringer Ingelheim and GSK. As a board member of Assobiotec, the Italian Association for the Development of Biotechnology representing over 100 companies and research institutes, he coordinates therapeutic areas including access, orphan drugs, advanced therapies, and clinical research.In the latest episode, Federico outlines Italy's ambitious plans to leverage its manufacturing heritage while addressing key barriers to help biotech companies scale from research excellence to commercial success. Read more

True Crime Tuesday presents The People Vs. The Golden State Killer with Attorney/District Attorney of Sacremento/Author, Thien Ho! In The People vs. the Golden State Killer, Thien Ho, the current District Attorney of Sacramento, recounts his harrowing and exhilarating experience as the lead prosecutor responsible for capturing and prosecuting Joseph DeAngelo. Referred to at various times by law enforcement and the media as the Visalia Ransacker, the East Bay Rapist, the Original Nightstalker, and finally the Golden State Killer, DeAngelo, a former policeman, is widely considered “one of the most notorious serial predators in American history.” Ho's book is the first official account of how the Golden State Killer was apprehended and put behind bars for life. Ho led an elite team of law enforcement from six California prosecutor's offices, using a newly developed tool known as “investigative genetic genealogy” to connect DeAngelo to multiple cold cases stretching back nearly a half century. Many previous narratives about DeAngelo, including two bestselling books and multiple documentaries, focused largely on the killer and his heinous crimes. This book not only provides hundreds of facts and details never revealed to the public about the Golden State Killer's crimes, it also presents the real-life story of the people who worked tirelessly to bring DeAngelo to justice. It also offers the unprecedented authorized perspective of three survivors of DeAngelo's crimes who courageously turned their pain into empowerment and activism. A portion of the book's proceeds will be donated both by the author and Third State Books to Phyllis's Garden, a nonprofit advocating for victims' rights begun in honor of a GSK survivor. On Today's True Crime Tuesday, we talk to Thien Ho about how he and his family fled from Vietnam in the early 70's, and how he went from not even knowing English when he came to this country, to wanting to defend his fellow citizens from the worst of the worst!  We talk about how he got the case of Joseph DeAngelo assigned to him, the challenges he had to overcome to get an indictment and then a conviction, and then justice for the victims that, for the first time in his career, he made a PROMISE that he would deliver a guilty verdict to!   PLUS AN ALL-NEW DUMB CRIMES/STUPID CRIMINALS W/TRAVIS THORPE! See the video of the trio that tried to break down the door of an Alexandria family while wearing Halloween costumes! :  https://www.wusa9.com/article/news/local/virginia/trio-halloween-masks-caught-on-camera-alexandria/65-48684b04-8dea-47ed-9b07-1aa6a65ae6dc?utm_source=fark&utm_medium=website&utm_content=link&ICID=ref_fark# Pre-Order your copy of  "The People Vs. The Golden State Killer" here:  https://bit.ly/4hnzBIH Sign up to go with Dacre Stoker and Mysterious Universe Tours to Romania here:  https://www.mysteriousadventurestours.com/darkness_radio/ Want to attend JUST Dracula's Vampire Ball at Bran Castle? Click this link to find out how: https://www.mysteriousadventurestours.com/darkness_radio/ Travel with Brian J. Cano to Ireland for Halloween for 11 days and get 100 dollars off and break it into 10 easy payments here:  https://www.mysteriousadventurestours.com/darkness_radio/ Make sure you update your Darkness Radio Apple Apps! and subscribe to the Darkness Radio You Tube page:  https://www.youtube.com/@DRTimDennis There are new and different (and really cool) items all the time in the Darkness Radio Online store at our website! . check out the Darkness Radio Store!   https://www.darknessradioshow.com/store/ #crime #truecrime #truecrimepodcasts #truecrimetuesday #thienho #thepeoplevsthegoldenstatekiller #goldenstatekiller #thirdstatebooks #murder #serialkillers #truecrimebooks #joesphdeangelo #visaliaransacker #eastarearapist #originalnightstalker #sacremento #murderinvestigation #orangecounty #rape #sexualassault #phyllissgarden #dumbcrimesstupidcriminals #TimDennis #travisthorpe #combatrev #floridaman #drugcrimes #foodcrimes #stupidcrimes #funnycrimes  #sexcrimes 

Next-generation platforms and technologies are getting closer to cracking one of biopharma's biggest problems: delivering medicines, and mAbs in particular, to the brain. On the latest BioCentury This Week podcast, BioCentury's Selina Koch details the latest innovations in blood-brain-barrier shuttles and how the technologies could transform the treatment of neurological diseases.BioCentury's Lauren Martz discusses her conversation with Tony Wood, CSO of GSK, which included the pharma's strategy for indication expansion, why it prefers RNA modalities over AAV-based gene therapies, and how its quest for causal biology has evolved over the years.Washington Editor Steve Usdin discusses the first set of FDA's new commissioner's national priority review vouchers, and why the voucher program is unlikely to function as an incentive capable of steering future behavior. Usdin also discusses the potential impact of FDA staffing reductions on the sector. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657326#BloodBrainBarrier #Neurology #DrugDelivery #MonoclonalAntibodies #RNAtherapeutics #CausalBiology #FDA00:01 - Sponsor Message: Evotec01:57 - Brain Shuttles13:57 - GSK Q&A20:08 - FDA VouchersTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

True Crime Tuesday presents The People Vs. The Golden State Killer with Attorney/District Attorney of Sacremento/Author, Thien Ho! In The People vs. the Golden State Killer, Thien Ho, the current District Attorney of Sacramento, recounts his harrowing and exhilarating experience as the lead prosecutor responsible for capturing and prosecuting Joseph DeAngelo. Referred to at various times by law enforcement and the media as the Visalia Ransacker, the East Bay Rapist, the Original Nightstalker, and finally the Golden State Killer, DeAngelo, a former policeman, is widely considered “one of the most notorious serial predators in American history.” Ho's book is the first official account of how the Golden State Killer was apprehended and put behind bars for life. Ho led an elite team of law enforcement from six California prosecutor's offices, using a newly developed tool known as “investigative genetic genealogy” to connect DeAngelo to multiple cold cases stretching back nearly a half century. Many previous narratives about DeAngelo, including two bestselling books and multiple documentaries, focused largely on the killer and his heinous crimes. This book not only provides hundreds of facts and details never revealed to the public about the Golden State Killer's crimes, it also presents the real-life story of the people who worked tirelessly to bring DeAngelo to justice. It also offers the unprecedented authorized perspective of three survivors of DeAngelo's crimes who courageously turned their pain into empowerment and activism. A portion of the book's proceeds will be donated both by the author and Third State Books to Phyllis's Garden, a nonprofit advocating for victims' rights begun in honor of a GSK survivor. On Today's True Crime Tuesday, we talk to Thien Ho about how he and his family fled from Vietnam in the early 70's, and how he went from not even knowing English when he came to this country, to wanting to defend his fellow citizens from the worst of the worst!  We talk about how he got the case of Joseph DeAngelo assigned to him, the challenges he had to overcome to get an indictment and then a conviction, and then justice for the victims that, for the first time in his career, he made a PROMISE that he would deliver a guilty verdict to!   PLUS AN ALL-NEW DUMB CRIMES/STUPID CRIMINALS W/TRAVIS THORPE! See the video of the trio that tried to break down the door of an Alexandria family while wearing Halloween costumes! :  https://www.wusa9.com/article/news/local/virginia/trio-halloween-masks-caught-on-camera-alexandria/65-48684b04-8dea-47ed-9b07-1aa6a65ae6dc?utm_source=fark&utm_medium=website&utm_content=link&ICID=ref_fark# Pre-Order your copy of  "The People Vs. The Golden State Killer" here:  https://bit.ly/4hnzBIH Sign up to go with Dacre Stoker and Mysterious Universe Tours to Romania here:  https://www.mysteriousadventurestours.com/darkness_radio/ Want to attend JUST Dracula's Vampire Ball at Bran Castle? Click this link to find out how: https://www.mysteriousadventurestours.com/darkness_radio/ Travel with Brian J. Cano to Ireland for Halloween for 11 days and get 100 dollars off and break it into 10 easy payments here:  https://www.mysteriousadventurestours.com/darkness_radio/ Make sure you update your Darkness Radio Apple Apps! and subscribe to the Darkness Radio You Tube page:  https://www.youtube.com/@DRTimDennis There are new and different (and really cool) items all the time in the Darkness Radio Online store at our website! . check out the Darkness Radio Store!   https://www.darknessradioshow.com/store/ #crime #truecrime #truecrimepodcasts #truecrimetuesday #thienho #thepeoplevsthegoldenstatekiller #goldenstatekiller #thirdstatebooks #murder #serialkillers #truecrimebooks #joesphdeangelo #visaliaransacker #eastarearapist #originalnightstalker #sacremento #murderinvestigation #orangecounty #rape #sexualassault #phyllissgarden #dumbcrimesstupidcriminals #TimDennis #travisthorpe #combatrev #floridaman #drugcrimes #foodcrimes #stupidcrimes #funnycrimes  #sexcrimes 

Te dejo aquí el enlace para votar a La Teoria de la Mente para los premios Ivoox: https://go.ivoox.com/wv/premios25?c=4271 ¿Cómo puede ser que invirtamos más que nunca en salud mental y, sin embargo, cada vez estemos peor? En este impactante análisis, basado en el libro "Sedados" de James Davies, exploramos cómo la psiquiatría moderna ha sido moldeada más por intereses económicos que por la evidencia científica o el bienestar de los pacientes. Acompáñanos en este viaje revelador donde desmantelamos el sistema actual de salud mental: desde los escándalos de la industria farmacéutica hasta la medicalización de la vida cotidiana, pasando por el estigma, la ideología neoliberal y los mecanismos que nos han convertido, literalmente, en una sociedad sedada. Descubrirás cómo grandes farmacéuticas como Pfizer, GSK o Abbott han sido multadas por prácticas fraudulentas, cómo se han inventado enfermedades para expandir mercados, y cómo el sufrimiento humano se ha transformado en una mercancía rentable. Mientras los avances médicos han salvado millones de vidas físicas, la salud mental ha permanecido estancada o incluso ha retrocedido. Y no es por falta de fármacos o diagnósticos… es porque el sistema está diseñado para mantenernos funcionales, no felices. Analizamos también los mecanismos ocultos: El auge del modelo biomédico y su compatibilidad con el capitalismo. La patologización de emociones humanas normales. El conflicto de interés entre psiquiatría y farmacéuticas. La despolitización del sufrimiento y su uso como herramienta de control social. Este video no es antipsiquiatría, es un llamado urgente a cuestionar un modelo que cosifica el sufrimiento, individualiza la culpa y silencia la posibilidad de cambio estructural. ️ Como dice James Davies, quizá nuestro malestar no sea una disfunción, sino una señal de que el mundo necesita transformarse. Si alguna vez has sentido que algo no encaja con el tratamiento que se le da a la salud mental... este video es para ti. Enlaces importantes Nuestra escuela de ansiedad: www.escuelaansiedad.com Nuestro nuevo libro: www.elmapadelaansiedad.com Visita nuestra página web: http://www.amadag.com Facebook: https://www.facebook.com/Asociacion.Agorafobia/ Instagram: https://www.instagram.com/amadag.psico/ ▶️ YouTube AMADAG TV: https://www.youtube.com/channel/UC22fPGPhEhgiXCM7PGl68rw Palabras clave (keywords SEO) James Davies,sedados libro,psiquiatría crítica,big pharma,industria farmacéutica,salud mental y capitalismo,medicalización de la vida,DSM diagnóstico,crítica salud mental,ansiedad y sistema,modelo biomédico,antidepresivos fraude,glaxosmithkline paxil,pfizer y salud mental,enfermedades inventadas,estigmatización salud mental,antipsiquiatría moderna,neoliberalismo y salud,sistema de salud mental,sufrimiento emocional,sociedad sedada,marketing farmacéutico,desequilibrio químico,problemas estructurales,comodificación del sufrimiento Hashtags para posicionamiento #SaludMental #BigPharma #PsicologíaCrítica #Sedados #IndustriaFarmacéutica #JamesDavies

Far from a future add-on, artificial intelligence is already embedded in the cycle of drug safety, from case processing to signal detection. Versatile generative AI models have raised the bar of possibilities, but they have also increased the stakes. How do we use them without losing trust and where do we set the limits?In this two-part episode, Niklas Norén, head of Research at Uppsala Monitoring Centre, unpacks how artificial intelligence can add value to pharmacovigilance and where it should – or shouldn't – go next.Tune in to find out:Why pharmacovigilance needs specific AI guidelinesHow a risk-based approach to AI regulation worksWhere in the PV cycle is human oversight most neededWant to know more?In May 2025, the CIOMS Working Group XIV drafted guidelines for the use of AI in pharmacovigilance. The draft report received more than a thousand comments during public consultation and is now being finalised.Earlier this year, the World Health Organization issued guidance on large multi-modal models – a type of generative AI – when used in healthcare.Niklas has spoken extensively on the potential and risks of AI in pharmacovigilance, including in this presentation at the University of Verona and in this Uppsala Reports article. His favourite definition of AI remains the one proposed by Jeffrey Aronson in Drug Safety.For more on maintaining trust in AI, revisit this interview with GSK's Michael Glaser from the Drug Safety Matters archive.The AI methods developed by UMC and cited in the interview include: vigiMatch for duplicate detectionvigiGroup for clusteringvigiRank for signal detectionvigiGrade for case report completeness scoringWHODrug Koda for automated coding Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we promote safer use of medicines and vaccines for everyone everywhere.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of major advancements and strategic moves that are shaping the future of healthcare.A significant development comes from AstraZeneca, which has committed a substantial $445 million investment to bolster production at its Texas facility for Lokelma, a treatment designed for hyperkalemia. Hyperkalemia is a condition characterized by elevated potassium levels in the blood, posing serious health risks if not managed properly. This investment highlights AstraZeneca's dedication to meeting growing global demand and enhancing patient access to this vital treatment. By strengthening its production capabilities, the company aims to ensure a more reliable supply chain, potentially leading to better outcomes for patients worldwide.Meanwhile, Pfizer is making noteworthy progress in the realm of oncology. Recent clinical trial results have positioned Tukysa, developed in collaboration with Seagen, as a promising candidate for first-line maintenance therapy in HER2-positive breast cancer. The potential shift from second-line to first-line treatment could significantly alter patient care by offering an effective therapeutic option earlier in the disease management process. This advancement underscores Pfizer's commitment to improving long-term outcomes for patients battling this aggressive form of cancer.In legal news, a dispute between Novo Nordisk and KBP Pharmaceuticals has underscored the critical importance of transparency and thorough due diligence in biotech transactions. The controversy involves "anomalous" phase 2 clinical trial results that Novo Nordisk claims were not adequately disclosed by KBP. Such cases highlight the necessity for rigorous investigation during mergers and acquisitions to prevent costly legal battles and ensure informed decision-making in drug development partnerships.On the HIV prevention front, GSK has released promising data for its long-acting pre-exposure prophylaxis drug, Apretude. This new data suggests Apretude holds higher acceptability compared to Gilead's competing product, Yetztugo. Improved patient adherence could shift market dynamics towards GSK's favor, potentially enhancing public health outcomes by preventing HIV infections more effectively.Manufacturing innovations are also taking center stage as Particle Dynamics collaborates with a former EuroAPI plant to introduce Codis, a new contract development and manufacturing organization (CDMO). Codis will offer comprehensive services such as spray drying and particle engineering, aligning with growing demand for specialized pharmaceutical manufacturing capabilities.Turning our attention to diabetes treatment advancements, Eli Lilly's oral GLP-1 candidate Orforglipron has demonstrated superiority over both placebo and AstraZeneca's Farxiga in phase 3 trials for type 2 diabetes. This success strengthens Eli Lilly's portfolio in a highly competitive market and could lead to regulatory approval next year. An oral treatment option could significantly enhance patient compliance compared to existing injectable GLP-1 therapies.In oncology, Boehringer Ingelheim has entered into a deal worth up to $991 million with AimedBio, focusing on antibody-drug conjugates (ADCs) that target proteins involved in tumor growth and resistance. This collaboration highlights the increasing interest in ADCs as targeted cancer therapies capable of minimizing systemic toxicity while delivering potent cytotoxic agents directly to cancer cells.The industry continues to be shaped by funding rounds and strategic acquisitions. Novo Nordisk's acquisition of Omeros' MASP-3 inhibitor Zaltenibart for $2.1 billion marks a significant move in rare disease therapeutics. Despite Omeros pausing development, Novo Nordisk sees potential in treating paroxysSupport the show

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

PRmoment founder Ben Smith is interviewed by Eilizabeth Giles about the speaker line up for PR Masterclass series The Agency Growth Forum and why it has become a bit of a personal challenge.What PR Masterclass: The Agency Growth Forum covers in one day is incredible. You get to hear the real experts talk about how to overcome the key challenges that PR firm owners are having right now when it comes to growth.As always with our PR Masterclass series, there are absolutely no sponsors. We don't believe in charging delegates for a ticket and then filling the program with sponsored slots.When, Where: Wednesday 26th November 2025Virtual tickets from £230 +VAT. Face-to-face from £460 +VAT, buy your ticket before 10/10/25 to get these early bird rates.Here's a run down of what Ben and Elizabeth talk about on the show:Why did we choose Rachel Bell to speak at the Agency Growth Forum?Let's just run through Rachel's PR agency CV:Founder, ShineCo founder, Mischief Co founder, The Academy Co founder, John DoeCo founder, AdhuroNon executive chair, Cavendish Enough said?Why did we choose Jonny Bentwood to speak at the Agency Growth Forum?There's an interesting global community of about 8-10 PR firm data geeks who are at the arrowhead PR and technology. Jonny's at the tip of that arrow.No PR Agency Growth Forum event would be complete without an analysis of PR's GEO opportunity and here Jonny will update us with the latest thinking.Why did we choose Rachael Marshall to speak at the Agency Growth Forum?Her firm Magic Digits has circa 30 PR agency clients and so there's no-one better to give a third party insight into the financial trends and challenges of running a PR firm today.In house panel: What do clients want?Bieneosa Ebite, GSK, head of communications and government affairs, inclusionClara Biu, Allwyn UK, head of consumer communicationsCharlotte West, Lenovo, vice president, global corporate communicationsWhy did we choose Rachel Friend to speak at the Agency Growth Forum?Rachel's had success at PR firms who are part of the holding groups and she's also had success at PR firms who are independent.So she knows how to run PR agency businesses. Rachel's going to talk to us about how to re-energise your PR businesses and get your momentum back.Why did we choose Jo Carr to speak at the Agency Growth Forum?For about the last 10 years PR firms have, in the main, worked hard to improve their employer brand and to become better employers.Jo was at the start of this trend. She understood that in a consultancy business where creativity and customer service are absolutely vital, happy employees are always going to mean happy clients.Why did we choose Paul Nolan to speak at the Agency Growth Forum?As this is the Agency Growth Forum, I didn't just want a PR AI expert, I wanted the PR leader who was furthest along the road integrating AI into their agency. That's why Paul's speakingWhy did we choose Jackie Elliot  to speak at the Agency Growth Forum?If you know, you know.Independent PR agency panel: The growth challengeThis panel will give an insight into the growth challenges for independent agencies at the moment.Why did we choose Lee Beattie to speak at the Agency Growth Forum?Lee is going to talk about how Joe Doe has had success in developing a culture where young people can thrive.

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 3, 2025. In this episode: Pfizer's backroom US pricing deal; confusion over Japan's pharma tariffs; more direct-to-patient schemes in the US; first approval for Novartis's remibrutinib; and GSK's CEO to step down. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-NYTAMV4KPFCB3PSCCQMKIF2CEA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Tariffs, drug pricing reform, a government shutdown and a major turnover at one of the world’s largest drugmakers all converged this week, leaving plenty to unpack for the industry as it heads into fall. Greater clarity on President Donald Trump’s tariff and pricing strategies has likely come as something of a relief for those companies operating in the U.S., but that news was tempered by a shutdown of the federal government on Wednesday. Meanwhile, big changes are likely on the way at GSK, whose longtime CEO Emma Walmsley is headed for the exit. In this week’s episode of "The Top Line," we break down some of the biggest stories across Fierce Pharma for the week—which may very well be some of the biggest stories of the year—touching on critical policy updates in the U.S., the furloughing of federal employees at agencies like the FDA and NIH and the imminent departure of GSK’s chief executive. Fierce Life Sciences’ Ben Adams sits down with Fierce Pharma's Fraiser Kansteiner to discuss the latest headlines and go over the key points from each major development that has played out. To learn more about the topics in this episode: FDA avoids the worst amid government shutdown, but new applications put on hold NIH research grinds to a halt as government shuts down Pfizer offers price concessions, $70B US outlay in Trump's 'most favored nation' push Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels See omnystudio.com/listener for privacy information.

Chinmay Sharma | HR Business Leader, Performance Emerging Markets ,GSKChinmay is an HR leader with 22 years of diverse experience in organizations like Procter & Gamble (2003-2012), Philip Morris International (2012-2020) and Glaxo Smithkline (Dec 2020 – till date)Chinmay has done roles across HR domains (Factory HR, Rewards, Talent Acquisition, Business Partnering) at Country, Region and Global level. He is very passionate about driving change and has a successful track record in shaping inclusive, diverse and performance driven work cultures by developing people and helping them identify their purpose in alignment with the company vision. He is also an accomplished coach focusing on enhancing personal leadership and performance effectiveness. He was recognized by HRD Asia magazine as “Top 20 Asia HR Directors in 2020” and “India's Most Impactful CXOs” by ET Now in 2023.Chinmay is currently transitioning to a new role as HR Business Leader for Performance Emerging Markets for GSK and is in process of relocating to London. Prior to this, he was the CHRO for GSK India where he successfully led the cultural transformation of a 100 years legacy company to become an agile, innovative and technology driven organization with thriving talents and leaders.Chinmay has lived and worked in India, Malaysia, Hong Kong and Switzerland. He got educated at Rajasthan University, Jaipur; SCMHRD (Symbiosis, Pune) and Cornell University, New York. He enjoys playing Tennis, listening to Indian semi-classical music & loves reading autobiographies. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. President Trump has once again delayed the imposition of 100% tariffs on pharmaceuticals, with preparations now set to begin on October 1. Halozyme's acquisition of Elektrofi for $900 million has brought two major pharmaceutical partners together, while Takeda is exiting the cell therapy sector and laying off 137 employees. Roche's $3.5 billion takeover of 89bio was driven by the success of Akero's drug, with regulatory documents shedding light on how 89bio's board pushed for the deal. Lotte Biologics is making waves as a multinational CDMO partner with a focus on quality and patient promise. In other news, GSK has announced layoffs, Pfizer has struck a drug pricing deal with Trump, and big pharma companies are exploring M&A funding opportunities. Stay tuned for more updates in the biopharma industry.Support the show

This week, the American FDA announced it's set to review a new breast cancer drug, Enhertu, developed by AstraZeneca (AZN) and its Japanese partner, Daiichi Sankyo. Julian Hofmann and Dan Jones unpack what this did to Astra's shares, the wider issues facing pharmaceutical companies, plus an update on GSK's (GSK) newest CEO.Next, our Big Read on the ways to effectively pass on your wealth. In the UK, estimates suggest up to £7tn could be transferred from older to younger generations over the next 30 years. Val Cipriani, author of the piece, explains what the “Great Wealth Transfer” means for investors, the trade-off gifters need to consider, and more. Last up, results from Ceres Power (CWR) came in lower than expected. Mark Robinson unpacks the reasons behind it, German shareholder Bosch's departure, and where the valuation stands.Timestamps1:23 AstraZeneca14:53 Passing on wealth 27:40 Ceres PowerRead more on these topics:A pharma giant with star quality How to pass on wealth to your childrenCeres Power cuts revenue guidance for 2025 Hosted on Acast. See acast.com/privacy for more information.

Charlene Young and Danni Hewson are your hosts this week, delving into the latest money and markets news. The US government has shut down for the first time since 2018, with Republicans and Democrats locked in a blame game over spending. Danni runs through what this means for markets, the economy, and workers facing unpaid shifts until Washington can agree on a deal. [01:33] Back in the UK, it's Labour Party conference week, Charlene and Danni discuss Rachel Reeves' big speech and the market reaction. We also discuss revised GDP figures, and why households are saving more as economic uncertainty lingers. [06:53] In company news, the CEO of GSK is stepping down, Exxon announces job cuts as part of a restructure, and Greggs serves up a mixed trading update after a summer sales wobble.[12:12] Our guest interview this week is with Jacqueline Broers, Joint Portfolio Manager of the Utilico Emerging Markets Trust, which specialises in infrastructure and investment in emerging markets and has just celebrated its 20th anniversary. [20:59]. Finishing with personal finance, Charlene will outline what you should think about before accessing your pension tax-free cash and how to check if someone you know is missing out on the £1.5 billion in unclaimed child trust funds. [32:43]

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry. Fortress and Sentynl faced hurdles in securing FDA approval due to manufacturing issues, while the third quarter of the year witnessed a flurry of significant biopharma acquisitions.In response to their agreement with the government, Pfizer is offering drugs at a discount, showcasing their commitment to affordable healthcare. Amidst these developments, there is a growing need to redefine the future of UK biotech and explore advancements in medicine, such as Novartis' recent approval of an oral BTK inhibitor for chronic hives.The biopharma industry saw a surge in mergers and acquisitions during the third quarter, with some of the largest deals in recent history taking place. Big pharma companies have substantial financial resources available for M&A transactions, with traditionally conservative companies leading the way. However, a small percentage of life sciences M&A milestones have been paid since 2008, indicating that many deals are still pending.Conversations between the UK government and the pharma industry have hit roadblocks, leading to a slowdown in investment. Additionally, Promoveo Health, a prominent contract sales organization, offers top-tier field sales talent at competitive rates. In other news, GSK's CEO Emma Walmsley steps down after nearly a decade at the helm.Despite these shifts in the industry landscape, it is crucial to stay informed about upcoming webinars and events that offer valuable insights into the world of biopharma.Support the show

AI is on everyone's agenda, but what does it really mean for businesses, productivity, and the future of work?In this episode, Stuart sits down with Daniel Snell, Co-Founder of Arrival, a management consultancy that has worked with leaders across the globe to deliver systemic change and sustainable performance. With a keen focus on AI, Daniel has seen first-hand how organisations are grappling with its rapid rise and potential. Stuart and Daniel explore the latest trends shaping AI adoption and its impact on productivity, the risks and challenges businesses face when integrating new technology, and the parallels between today's AI revolution and the dawn of the internet. They also discuss whether AI can truly reduce workplace bias, how it might assess individual value and influence career progression, and what the future of AI in business could look like.About our guestFor more than 20 years, Daniel Snell has advised executive leaders worldwide—including those at Tesco, Investec, Sky, GSK, and Morgan Stanley—helping them drive growth, profit, and organisational performance. Known for bridging strategy, people, and organisational behaviour, he has delivered lasting change across industries and cultures. Alongside his consultancy work, Daniel leads Arrival's Social Impact programmes, which have supported over 15,000 disadvantaged young people into successful careers. He also founded the Not in Our Name movement during the 2011 London riots and is a finalist in the 2025 Consultancy Awards for his pioneering approach to inclusion.Arrival is backed by some of the UK's most recognised business and investment leaders, including figures from Pret, Tesco, Haleon, Artemis, Lansdowne Partners, Silverlake and ECI Partners.Key timestamps:01:50 – Introducing into Daniel Snell05:01 – Starting Arrival 14:01 - The impact of Covid on performance16:00 – Trends within AI18:52 – Risks when adopting AI 29:32 – AI breaking through to meritocracy 31:46 – AI's ability to remove bias in the workplace38:57 – The data AI needs to understand someone's value to an organisation41:09 – Technology compared to the human connection46:22 – AI impacting career progression49:29 – AI's impact on inclusivity 59:11 – What will AI look like in 10 years?You can listen to and download HR Insights from Apple Podcasts, Google Podcasts, Spotify and other popular podcast apps. Please subscribe so the latest episodes are directly available! You can also join our HR Community by following us on LinkedIn.Thank you for listening and please do review and rate us wherever you listen!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for specific operations to optimizing the entire production process. Additionally, Crystalys, backed by Novo, has debuted with $205 million to tackle gout with its drug dotinurad. The FDA recently singled out Aurinia Pharmaceuticals in a LinkedIn post about surrogate endpoints for lupus nephritis drugs, criticizing companies for not conducting post-approval studies to demonstrate benefits on hard clinical endpoints. Larimar's Friedreich's ataxia drug has faced concerns about anaphylaxis, causing shares to fall. GSK's CEO Emma Walmsley has stepped down after 9 years, resealing pharma's glass ceiling. Upcoming webinars will focus on topics such as mRNA medicine and biopharma in an age of deregulation.

Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year's fifth largest—came just a week after Pfizer acquired rising obesity star Metsera for $4.9 billion. Just seven days later, Metsera made the New York–based pharma look like a genius with mid-stage data for one of the deal's centerpiece therapies, MET-097i, showing 14% placebo-adjusted weight loss over 28 weeks.After months of tarrying and threats, President Donald Trump announced last week that 100% tariffs would take effect Oct. 1—with broad exceptions for companies that have taken steps to build out their domestic manufacturing footprints. One company that has answered that call—as well as a letter sent by the president to 17 of the largest pharma companies requesting action on his most-favored-nation drug pricing policy—is Pfizer. In a joint oval office announcement with Pfizer CEO Albert Bourla and HHS officials, Trump said Pfizer would offer all new medicines at MFN prices.Meanwhile, over at the FDA, CDER Director George Tidmarsh, who has flown relatively under the radar since taking the post in July, took to LinkedIn to address the subject of relying on surrogate endpoints in drug approvals. In a since deleted post, Tidmarsh called out Aurinia Pharmaceuticals' lupus drug as an “egregious” example of this phenomenon. CDER's sister agency, CBER, also made a splash last week, publishing three draft recommendations intended to accelerate the development of cell and gene therapies.Speaking of CGT, maybe the biggest clinical development news of the year emerged from this space last week when uniQure announced that its gene therapy for Huntington's disease, AMT-130, slowed disease progression by 75% after three years. With these data in hand, uniQure plans to file for FDA approval of the treatment in the first quarter of 2026. If successful, AMT-130 would be the first genetic therapy for the intractable neurodegenerative disease.Finally, biopharma's glass ceiling just got a little more tightly sealed. Emma Walmsley, the industry's first female CEO, is stepping down after nine years at GSK, handing the reins to current chief commercial officer, Luke Miels. When Walmsley officially departs on Dec. 31, she will leave Vertex CEO Reshma Kewalramani and incoming Takeda CEO Julie Kim to represent the sisterhood at the highest ranks of the biopharma industry.

Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech's largest step toward marketing its own pipeline. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the evolution of Genmab, which, for many years, relied on a partnership model that delivered blockbuster revenues but now is making a change as a patent cliff looms.The analysts also assess the tenure of Emma Walmsley the longtime CEO of GSK, and what's next for the U.K. pharma under incoming CEO Luke Miels. Turning to the U.S., Washington Editor Steve Usdin discusses President Donald Trump's looming tariff threat on imports of branded drugs, which Usdin says would hurt small biotechs the most. Usdin also analyzes the response of multinational pharmaceutical companies to the president's demand that they make “most favored nation” price concessions, now that Monday's deadline has passed. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/657131#biotech #pharma #deals #FGF21 #MASH #Interleukin5 #asthma #PhRMA #PBM #tarriff #MFN00:01 - Sponsor Message: IQVIA Biotech02:26 - Genmab's Merus Buy09:43 - CEO Switch at GSK17:22 - Trump Tariff Threat21:17 - MFN Drug PricingTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next year. The FDA's decision to disclose complete response letters in real-time has raised questions about transparency and the agency's role. Additionally, Biogen has shuffled staff after ending work on AAV, while Heidelberg has cut 75% of its staff after missed royalty payments.The FDA's real-time disclosure of complete response letters benefits investors by providing greater visibility into regulatory decisions. In September, the FDA's actions included boosting Keytruda while rejecting two spinal muscular atrophy therapies due to manufacturing issues. A judge's ruling on the FDA's authority over laboratory-developed tests reflects the impact of a recent Supreme Court decision. Six FDA decisions to watch for in Q4 could have significant implications for the biopharma industry and patients. Recent developments include positive results for an immuneering asset in pancreatic cancer, FDA approval for Lilly's oral SERD for breast cancer, and positive outcomes for uniQure's Huntington's therapy. Additionally, the FDA is streamlining development of cell, gene, and regenerative therapies. Other news includes the revival of a dormant drug as a potential autism treatment, setbacks in obesity studies, and unexpected rejections for certain therapies. Upcoming webinars and job opportunities are also highlighted.Listeners are encouraged to provide feedback on topics they would like to see covered in future episodes.

The 5 things you need to know before the stock market opens today: Jeep-maker Stellantis has a new CFO, the CEO of British drugmaker GSK is stepping down, SEC Chair Paul Atkins is moving to fast track President Trump's effort to shift the earnings report schedule for public companies, Vice President JD Vance has spoken publicly about TikTok, and Bad Bunny will headline this February's Super Bowl halftime show.  Squawk Box is hosted by Joe Kernen, Becky Quick and Andrew Ross Sorkin.  Follow Squawk Pod for the best moments, interviews and analysis from our TV show in an audio-first format. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber led off the show with the deal the day: Videogame publisher Electronic Arts has agreed to be taken private by Silver Lake Partners, Affinity Partners and Saudi Arabia's PIF  in a $55 billion buyout. The anchors reacted to comments by Walmart CEO Doug McMillon, who was quoted as saying "It's very clear AI is going to change literally every job." Changes in the C-suite: New CEOs at CSX,  Barrick Mining and GSK, while Comcast named its President Mike Cavanagh to join Brian Roberts as Co-CEO effective January 2026. Also in focus: Markets and government shutdown watch,President Trump reiterates his threat to impose 100% tariffs on movies filmed outside of the U.S., Jim's new book "How To Make Money In Any Market" goes on sale Tuesday. Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC.Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview three high school students who made less invasive EoE diagnostics the focus of a science fair project. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:51] Co-host Ryan Piansky introduces the episode, brought to you thanks to the support of Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:08] Holly introduces today's guests, three high school students from Texas who made EoE diagnostics the focus of a science fair project: Leyna, Nhu, and Jaden.   [1:47] Leyna, Nhu, and Jaden are best friends. Nhu was diagnosed with EoE last summer. Leyna said Nhu told them it took a long time for the doctors to diagnose her because they thought it could be different conditions.   [2:07] Nhu told them about her appointments and her endoscopy procedures. She had to miss school sometimes. Leyna and Jaden were concerned for her.   [2:22] Leyna took AP Bio. Her teacher was a sponsor for the science fair. Leyna thought this would be a meaningful project for the three friends to learn more about Nhu's condition.    [2:45] Holly shares that she wasn't diagnosed until her 20s, but she was sick for much of her childhood.   [3:13] Ryan shares that he was diagnosed when he was two, after two years of his parents taking him to different doctors and undergoing different tests.   [3:31] Nhu says it was hard to find a specialist. They found one and had to wait six months for an appointment. It was a long time, suffering from the effects of EoE with constant symptoms, a lot of heartburn, and painful vomiting.   [4:00] Nhu was diagnosed with EoE in her sophomore year of high school. Her friends have seen her endure a lot, but she's strong. Nhu had to miss an orchestra concert where she had a big solo, because of her EoE.   [4:32] Doctors thought Nhu could have something different, like H. Pylori or cyclic vomiting syndrome. They didn't have clear answers, which was confusing and frustrating for her family.   [4:50] Holly talks about how difficult it was for her to get a diagnosis, and how she was told she was vomiting to get attention. She shared her reaction when diagnosed. She would like someone to do a research study about the pain tolerance of people with EoE.   [5:41] Leyna says junior year is the hardest year of high school. She doesn't know how Nhu survived physics and AP classes with EoE on top of it, and making up late work.   [6:14] Nhu takes a weekly injection. Her symptoms happen almost monthly. Sometimes she misses school for two weeks and has to catch up on work. Leyna and Jaden help her with her schoolwork.   [6:47] Ryan shared how he missed a third of his senior year in high school. He's now on an injectable biologic that has helped him a lot. That treatment option wasn't available when he was in high school. Having supportive friends to send him his schoolwork and keep him up-to-date was very helpful.   [7:11] Ryan explains the esophageal string test (EST). This is a tool that was developed to help monitor eosinophilic esophagitis (EoE). The test works by having the patient swallow a capsule about the size of a Tic Tac that has a string attached.   [7:25] The capsule dissolves in the stomach while the string stays in place in the esophagus. After about an hour, it's gently removed. Along the way, the string collects samples from the lining of the esophagus, which are reviewed, similarly to a biopsy.   [7:37] Holly adds that what makes the string test unique is that it doesn't require an endoscope, anesthesia, or recovery time, things that usually come with a traditional endoscopy and biopsy.   [7:46] It's now being used with patients as young as four years old. While some people might feel some minor discomfort, it's generally much easier for regular monitoring than an endoscopy.   [7:57] Holly explains that she was involved in testing the device and developing a swallowing protocol for it at Children's Hospital of Colorado. We will talk more about this later in the episode.   [8:06] Ryan adds, to learn more about the development of the string test, listen to episode 26 of this podcast.   [8:10] The string test is one of multiple, less-invasive monitoring tools for eosinophilic esophagitis. Others include the sponge test and unsedated trans-nasal endoscopy.   [8:19] To learn more about unsedated transnasal endoscopy, listen to episodes 19 and 20, where we talk to clinicians and patients about this method.   [8:27] During that episode, we talked to the developers of the EST.   [8:38] Jaden tells how he, Leyna, and Nhu brainstormed ideas and decided to base their project specifically on how to diagnose EoE in a less invasive way than endoscopies.   [9:12] Before this project, they were not familiar with the EST. Nhu says her only option for diagnosis was an endoscopy.   [9:21] Holly says it's still like that in Maine. She came from an area of the country where the EST was researched, and it's interesting to her that she doesn't have access to it now.   [9:37] What appealed to the group about the EST as an alternative to endoscopies is that it was so different. There are so many advanced technologies, and the EST is just a capsule taped to a string. It is simple but innovative.   [10:13] Real Talk: Eosinophilic Diseases had Drs. Robin Shandas and Steven Ackerman, who were instrumental in the development of the esophageal string test, as guests on episode 26 of this podcast. Ryan encourages listeners to check out that episode at apfed.org/podcasts.   [10:42] They searched for keywords and analyzed a variety of scholarly literature. They collected a lot of data from Dr. Ackerman's papers.   [11:10] They also reached out to gastroenterologists on social media. A hard thing about science fair projects is coming up with an experiment. They didn't know what they could do just with compiled research, but they had a great sponsor who helped along the way.   [11:56] Leyna says they trusted that the doctors they reached out to on social media were competent in their understanding of different diagnostic methods. She notes that different locations may have different resources and different biases.   [12:14] Leyna says they talked to doctors in the U.S. and from different countries, including India and Mexico. She commented that communities in Mexico might not have the same resources as communities in the U.S. or India. That might change their understanding of the EST.   [12:33] We might have different biases because we don't have the same technology to research and find the same things about the EST.   [13:12] Leyna says they reached out to doctors on social media, but didn't get responses from that many doctors. Reaching out to patients would be a good thing if they want to continue the project.   [14:00] Jaden says most of the data they found was from Dr. Ackerman, including a survey he did comparing the data of the EST and the biopsies.   [14:10] They found that the EST and the biopsies were relatively similar in terms of discovering the eosinophilic count and determining whether the EoE is active or inactive.   [15:30] They found differences between ESTs and biopsies in finding how much of a certain chemical is in the patient's cells.   [14:43] Leyna comments that one of the doctors they reached out to told them about the sponge test, another less invasive method. They didn't research the sponge test, but it sounded interesting.   [15:00] Ryan says there are a lot of cool new techniques that are being researched, like the transnasal endoscopy that goes in through the nose, the string test, and the sponge test.   [15:13] Leyna says the cool thing was hearing about all these methods. They had hypothesized that there are less invasive methods that may be better than endoscopies.   [15:27] They were not able to prove their hypothesis yet. They learned a lot of different things that could be beneficial.   [15:42] Holly points out that the transnasal endoscopy is not scary. It's also known as the unsedated endoscopy. Holly has done both the EST and the unsedated endoscopy,  and they each have pluses and minuses.   [16:15] Nhu explains how the team would meet at one of their houses, usually Leyna's house. One day, they watched Interstellar together, and the “Eureka moment” scene motivated them.   [16:41] They helped each other whenever necessary. When the project board was due, they all went to Leyna's house to work on the project board. They worked together as a team.   [16:51] Jaden analyzed a lot of the data. Leyna reached out to professors. Nhu helped Jaden understand some terms. On the day they presented the project, Nhu was sick in the hospital, which made them sad. They included a photo of her on the project board.   [17:28] Holly says that although Nhu wasn't there, it may have helped people know how sick EoE can make you feel.   [18:28] Leyna says one of the doctors they reached through social media told them that endoscopies have lots of benefits. The biopsy samples give healthcare professionals a clear idea of how many eosinophils per high-powered field, a key indicator in diagnosing EoE.   [18:57] The diagnosis gives a baseline for starting treatment for the patient, monitoring how effective the treatment is. You can't count the number of eosinophils per high-powered field using the string test.   [19:11] The EST is a gelatin capsule attached to a long string that you swallow. It dissolves in the stomach. It's less expensive than an endoscopy.   [19:33] Holly says one of the big differences is that you can't diagnose EoE on a string test. It has to be diagnosed with an endoscopy.   [19:40] Leyna says they learned that from the doctors and medical students who reviewed their project board. You can't diagnose EoE with the EST, but you can monitor it.   [19:52] The string test doesn't provide a direct eosinophil count, but it reflects the level of inflammation in your esophagus, and it can measure the protein biomarkers. That correlates with the eosinophil count from a biopsy. It is good for monitoring EoE.   [20:12] Ryan says that's a great idea. In the show notes, there is a link to the diagnostic consensus guidelines. They specify that you need an endoscopy and 15 eosinophils per high-powered field to be diagnosed with EoE.   [20:28] The EST can monitor the progression of the disorder as you're trying new medicines or an elimination diet. If you need an endoscopy every three to six months, it can be taxing.    [20:49] Ryan comments on the cost. Going through anesthesia for an endoscopy is very expensive, and not everyone has the insurance to cover these diagnostic procedures. The EST is an option you can do in a doctor's office in just over an hour.   [21:16] Holly asks if Nhu has participated in a string test. Nhu has not, but she would love to do a string test if she had the chance. Whenever she sees her doctor, she brings up her condition, and what could be better for her, such as the string test.   [22:06] The science fair is a huge regional fair in Houston, called the Science and Engineering Fair of Houston (SEFH). This was their first year participating. They were regional qualifiers from their district. When they got there, everyone else had six-foot-tall printed boards. It was a shock to them.   [22:56] They hope to level up their board for next year's fair. It was cool and eye-opening to see all these student researchers and get feedback from the people who walked by their booth. They heard some interesting things to use in their next project.   [23:15] One medical student in attendance came by their project board and suggested that while the EST may not diagnose EoE, maybe it could be used as a screening tool [to help identify people who should follow up with a gastroenterologist for a diagnostic work-up]. Interestingly, this was a medical student, and she had recently scheduled an appointment with a gastroenterologist for an endoscopy to see if she has EoE.   [24:04] This student didn't seem to know much about EoE, but felt she was experiencing symptoms that might indicate EoE. She told them she had learned so much from their board. Ryan says it's great that the project was able to help this person.   [24:44] Jaden says that the students at their school didn't know much about EoE, but when they looked at the project board, they were shocked by how incredibly difficult it is to diagnose EoE and how the EST could change a lot of things as a screening method.   [25:11] Jaden says their science teacher came by to see their board and how they were doing. He liked how they included not only the research information but also the stories of why they chose their project and why they were passionate about it.   [25:34] The day of the project, Leyna and Jaden were sad that Nhu couldn't be there with them. Their sponsor, Leyna's biology teacher, was sick, but showed up at the fair to view their presentation. They raised awareness about EoE. People learned about it.   [25:54] When Nhu told Leyna about her EoE, Leyna had no idea what it was. She's glad their project brought the issue to the table. They emphasized that more research needs to be done. There is much we don't know about less invasive methods.   [26:23] Nhu has considered a career in medicine since she has been in many hospitals and talked to a lot of doctors. Jaden sees himself in the engineering field, but he enjoys researching like this and seeing things through a different perspective.   [27:05] Nhu learned a lot about herself with EoE. Leyna loves how much they learned from this project. She is interested in pursuing scientific research. She thinks it's cool that Ryan is a graduate student.   [27:24] Leyna just got back from a five-week summer research program. It was insightful. She doesn't see herself becoming a doctor, but possibly doing research and advocating for different conditions.   [27:43] When Ryan was in high school, with all his hospital time, he had an interest in medicine, then he took a turn into engineering. He enjoys research. He's passionate about engaging in patient advocacy work through APFED.   [28:10] Ryan is glad for Leyna, Nhu, and Jaden that they were able to engage with this research and do it as a group and as friends. He says it's fantastic to hear from the group about the whole process they went through.   [28:23] Holly asks, looking back on everything you guys learned and experienced in this project, what's one question or idea you would still like to explore if you had more time and resources?   [28:38] Nhu wants to research finding more ways to diagnose EoE. Testing for EoE and finding EoE are very interesting for her.   [28:53] Jaden thinks that if they had more time, they would try to create a model of the EST to show how it works. He would possibly try to improve upon the model or develop something new. Instead of just relying on the data we have, he would try to collect data.   [29:26] Leyna agrees. She would like to build a prototype, understand how the capsule works, and find out whether the string down the esophagus is uncomfortable.   [33:41] Ryan suggests there is a doctor who would let them try the string test so they could see how it feels. Holly tried the string test at a major children's hospital while it was being researched. She doesn't want to ask her patients to do something she hasn't done, since she has the diagnosis too.   [30:37] Ryan comments that he enjoyed hearing about the process of the project.   [30:51] Ryan gives a quick recap: The esophageal string test is a tool to help monitor EoE. It is not a tool to diagnose EoE. If you or a loved one has EoE or suspect that you might, ask your clinician about the string test to see if it's an option for you.   [31:03] Holly adds: School science fairs are one way to bring education about eosinophilic disorders to schools. We love hearing about community science fairs and school projects that teach others about these conditions.   [31:13] For those of you looking to learn more about eosinophilic esophagitis, we encourage you to visit apfed.org/EoE.   [31:23] For those looking to find specialists who treat EoE, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [31:30] Ryan thanks Leyna, Nhu, and Jaden for joining us today. Holly also thanks APFED's Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Dr. Robin Shandas Dr. Steven Ackerman “Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference”   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   “Nhu and Jaden are my best friends. Recently, Nhu was diagnosed with EoE. I remember her telling us about the long diagnosis process. It took the doctors quite a long time to diagnose her because they thought it could be different conditions.” — Leyna   “I thought that this would be a meaningful project for us to learn more about Nhu's condition [of EoE].” — Leyna   “The students at our school didn't know much about EoE, but when they looked at the project board, they were shocked by how incredibly difficult it is to diagnose EoE.” — Jaden   “One of the main benefits of the string test is that endoscopies can be quite expensive, especially the anesthesia. It could be beneficial for people who don't have the money for an endoscopy.” — Nhu

Ochelli Effect 9-25-2025 SNAFU NEWS OVERNIGHTActually went LIVE 530 AM EasternJust to get on it ahead of tomorrows shorts X Mess, and firestorm meltdowns , here we go...Let's start with a typical Americans target something that makes no sense because someone wants you to believe an unproven motive you may have forgotten from June of this year. NOTE all The MSM agree to play the BS Motive game especially when COPS who NNNEEEEEVVVVEEERRRRR Lie present BS without investigation or the narrative they or those that support them enjoy. We report, we decide and you keep buying it, should be the American MSM mantraLPhotos show Waymo vehicles on fire during LA protests as company cuts downtown servicehttps://www.cnbc.com/2025/06/09/photos-waymo-fire-la-protests.htmlRWaymo cars set on fire as Los Angeles immigration raids protests continuehttps://www.foxla.com/news/waymo-cars-fire-los-angeles-immigration-raids-protestsNow think critically if you can?Ochelli SEZ The Grouypers Strike againWitnesses say there were intentional pauses between shots that seemed as though targets were selected carefully and if true aside from bullets strikes the building all bullets landed on Detainees NOT ICE COPSGunman wrote 'ANTI-ICE' on unused bullet in fatal attack on Dallas immigration officehttps://www.reuters.com/world/us/three-injured-shooting-ice-facility-dallas-local-media-reports-2025-09-24/THE THING THEY SLIP BY YOU ON AUTISM WHILE IDIOTS ARGUE OVER HOW EFFECT or DESTRUCTIVE TYLENOL IS = THE NEW QUID PRO OR QUO THAT IS A BRAND NEW SHINY FDA APPROVAL FOR A LEGACY DRUG COMPANY THAT CHANGED IT's NAMES and MERGERS with MERGERSGSK plc is a publicly traded company, so it is owned by its shareholders. Major shareholders include institutional investors like The Vanguard Group, BlackRock, and Schroder Investment Management Ltd.. The company was formed in 2000 by the merger of Glaxo Welcome and SmithKline Beecham, creating a multinational pharmaceutical and biotechnology company headquartered in London.RIGHT AFTER THE SILENT DEAL CUT AS REAL REPS OF CORPOARTION AMERCAN DREAM ALLOWED TRUMP TO EAT (whatever they hell they served) OVER AFTER HIS PLATDATE WITH LESSER ROYAL CHARLES in WINDSOR where EPSTEIN IMAGES bounced off the wall DOUBLED THE DISTRACTION. AFTER ALL every devil knows IN PERSON is the only way you TO SELL LIVES OR SOULS. FDA, in unusual step, aims to repurpose old GSK drug as autism treatmentAfter reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling more than two decades ago — for a condition associated with autism.https://www.biopharmadive.com/news/fda-gsk-wellcovorin-leucovorin-autism-cerebral-folate-deficiency/760840/So a little false hope and a bottle of lame alleged vitamins land on the hot shelf, and Ochelli bets A.J. is pissed he didn't get in on that medicine showhttps://www.newsnationnow.com/health/what-leucovorin-treat-autism/AS THE WORM TURNS... in RFK Jr's Brain I guess...---IN OTHER SPORTS and WWE R THE WORLD HIGHLIGHTSMLB is now going to the Video game Style ABS system for making sure Balls and Strikes get called without having to factor in Umpire Bias. Too bad they are about 30 years late on that. Also too bad we can't have a BS meter on any screen where American Politicians open their mouths!https://www.mlb.com/news/abs-challenge-system-mlb-2026Press Secretary Leavitt alleged intentional sabotage by UN staff after an escalator stopped while the Trumps were on it and a teleprompter failed during the president's speech. https://www.facebook.com/photo.php?fbid=3493045087501295&set=a.101711856634652&type=3AND IF YOU CAN'T ACCEPT FED-BOOK I know you'll accept FOX NEWSFox News host Jesse Watters says the US should bomb the UN over Trump's broken escalatorhttps://www.the-independent.com/tv/news/trump-escalator-un-bomb-us-jesse-watters-video-b2832888.htmlIf you give a toddler an army and nuclear code He will get some Ice Cream.Orange Jesus already delivered his BS to the U.N. before FOX even had time to start Griping and casually suggesting eliminating those who dare defy LORD TRUMPFact-check: Trump misleads about ending 7 wars, US economy, renewable energy in UN speech https://www.politifact.com/article/2025/sep/23/trump-un-general-assembly-speechIf YOU GASLIGHT THE GASLIT HOW MANY FIRES DOES A GASLIGHT LIGHT IF A LIGHT COULD BE BRIGHT?Italy sends warship to accompany Gaza flotilla following Israeli attackhttps://www.middleeasteye.net/news/footage-shows-apparent-attack-gaza-bound-global-sumud-flotillaBTW no article or REFERENCE LINKS but Jay Z has a lot of rumored issues with allegations flying about Paternity, Connections to Puffy, Underage Partners, Hush Money, Divorce, and Maybe getting Too much Destiny out of Beyonce's Besties in Destiny's Child. So Plenty of Drama that maybe has an In Law Mama keeping the facade of a hip-hop pop empire intact.From the bottom of The Ochelli Heart, Even though I see Black Twitter, and Respect 50 Cent, I just can't bother to care, except I miss when this might have been the scandal that was the why is America so stupid international Press I just can't muster the energy to give a full shit. Government Shutdowns Q&A: Everything You Should Knowhttps://www.crfb.org/papers/government-shutdowns-qa-everything-you-should-knowFROM THE KIMMEL KENNEL Trump slams Kimmel's return: "We're going to test ABC out on this"https://www.axios.com/2025/09/24/trump-jimmy-kimmel-return-abcWhat Really pissed off Donald?Jimmy Kimmel's first show back on September 24, 2025, drew approximately 6.26 million viewers, a significant increase from his previous average of around 1.77 million viewers in the second quarter of 2025. This represents a viewership increase of roughly 250% compared to his recent average, making it the show's highest-performing regularly scheduled episode in over a decade.and that was just his LIVE viewers without all of the regular channels participating.Meanwhile Southpark Pussyed out last week in the hot kitchen then released "Conflict of Interest" EPISODE 5 of the current season into LOOney Tunes Lame 2025. Spoiler, It wasn't worth talking aboutwebelos kid Maybe a dude or a chickPrediction Marketing Betting AppsGazza Satan and Trump are having a baby Trump makes a little PLAN B SoupApps and Undue Influence Via Social MediaKyle's Mom is gonna Strike Gazza MaybeI wouldn't want to be a hospital in PalestineALSOIT'S FAT BEAR WEEKhttps://www.theguardian.com/us-news/live/2025/sep/25/donald-trump-james-comey-fbi-ice-texas-latest-us-politics-news-updates-liveFormer FBI director James Comey expected to be indicted on criminal charges, reports say – US politics liveCharlie Kirk https://www.youtube.com/shorts/BGRhw0C7JL0Mark Cubanhttps://www.youtube.com/shorts/x7AuftuT04wA Very Strong Case https://www.youtube.com/watch?v=KrU6F-S8VMo---BE THE EFFECTEmergency help for Ochelli and The NetworkMrs.OLUNA ROSA CANDLEShttp://www.paypal.me/Kimberlysonn12 new Social Media experimentsBLUESKYhttps://bsky.app/profile/ochelli.bsky.socialTRUTH SOCIALhttps://truthsocial.com/@Ochelli---NOVEMBER IN DALLAS LANCER CONFERENCEDISCOUNT FOR YOU10 % OFF code = Ochelli10https://assassinationconference.com/Coming SOON Room Discount Details The Fairmont Dallas hotel 1717 N Akard Street, Dallas, Texas 75201BE THE EFFECTListen/Chat on the Sitehttps://ochelli.com/listen-live/TuneInhttp://tun.in/sfxkxAPPLEhttps://music.apple.com/us/station/ochelli-com/ra.1461174708Ochelli Link Treehttps://linktr.ee/chuckochelliAnything is a blessing if you have the meansWithout YOUR support we go silent.---NOVEMBER IN DALLAS LANCER CONFERENCEDISCOUNT FOR YOU10 % OFF code = Ochelli10https://assassinationconference.com/Coming SOON Room Discount Details The Fairmont Dallas hotel 1717 N Akard Street, Dallas, Texas 75201. easy access to Dealey Plaza

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 19, 2025. In this episode: GSK announces US investments during Trump's UK visit; Lilly thinks twice about UK lab investment; analyzing the rise in China R&D and deals; Regeneron CEO on his company's ignored blockbusters; and AstraZeneca's COPD trial failure. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-D4VJFG2XNJGAJEFGSXNEQUA3BU/ Sign up for China R&D webinar: https://www.citeline.com/en/events/china-transforming-pharma This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

The FDA Group's Nick Capman speaks with Catherine Lunardi, Founder and CEO of GenAIz. With nearly a decade leading GenAIz and prior leadership roles at GSK, CGI, and Héma-Québec, Catherine brings a seasoned perspective on how life science organizations can practically and compliantly deploy AI to build the next generation of labs.Catherine explains the biggest challenges labs face today—like fragmented data, manual processes, and costly compliance reviews—and how AI can help orchestrate data, surface anomalies, and accelerate insights without replacing the people at the center of science. She outlines a step-by-step approach to identifying the right challenges, aligning AI projects with company strategy, piloting solutions with clear ROI, and managing change so teams embrace and sustain new tools.Nick and Catherine also discuss the balance between innovation and regulation, how to keep humans in the loop, and why strong governance and explainability are essential to ensuring AI adds real value in GLP environments.About The FDA Group: The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations: ⁠https://www.thefdagroup.com/

Sir Jon Symonds, Chair of GSK was Bina's first guest when Pull up a Chair launched in 2022. Three years on, Jon returns to give an update on what the world has learned since: geopolitically, economically and technologically. Can health systems do more than just treat sickness? Hear the highlights from their conversation in under 10 minutes. This episode is part of Pull Up a Chair's ‘Insights' series, featuring bite-sized perspectives and advice from podcast guests.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly's oral weight loss pill, orfoglipron, has faced challenges in meeting expectations, possibly due to an over-representation of males and Hispanic patients in the phase III study. The company is now presenting detailed late-stage data to paint a competitive profile for the drug. Meanwhile, the FDA has targeted Lilly and Novo Nordisk for downplaying risks of their GLP-1 weight loss drugs in advertising, particularly during a prime time special with Oprah Winfrey. Lilly is also investing in a $5 billion manufacturing plant in Virginia, part of a larger $27 billion U.S. investment plan.In other news, GSK is committing $30 billion to boost R&D and manufacturing operations in the U.S., showing a strong commitment to innovation. Additionally, advancements in AI-driven antibody discovery technology by Sino Biological are revolutionizing the field of biotechnology. The pharmaceutical industry is facing tightening oversight and regulatory changes, as well as exploring predictive care powered by consumers and AI technology.This dynamic landscape highlights the importance of staying informed and adaptable in the ever-evolving world of Pharma and Biotech.

President Trump's state visit to the UK has coincided with a flurry of multi-billion investments in British tech industries. But among the good news, there's money travelling in the opposite direction, with UK pharma giant GSK announcing massive investment in the US. And, for the UK steel industry there's disappointment, as hoped-for cuts to tariffs on UK exports to the US come to nothing. Sean Farrington looks and what's coming in, what's going out and what's staying the same with Microsoft CEO Satya Nadella and expert voices from the UK steel industry and the financial markets.

Miércoles clave en los mercados globales: la atención está puesta en la Reserva Federal y las nuevas señales de política monetaria, mientras empresas de tecnología, banca y entretenimiento protagonizan movimientos importantes: